Randomized open label phase 3 study of adjuvant sacituzumab govitecan and pembrolizumab vs treatment of physician's choice in patients with triple negative breast cancer

Project: Research

Status	Active
Effective start/end date	03/5/24 → 03/4/27

Project Details